Sutro Biopharma (NASDAQ:STRO) Rating Reiterated by Wedbush

Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $8.00 price target on the stock. Wedbush’s target price suggests a potential upside of 103.56% from the stock’s previous close. Several other equities analysts have […]

Leave a Reply

Your email address will not be published.

Previous post Truist Financial Corp Purchases 2,919 Shares of EQT Co. (NYSE:EQT)
Next post Tee Thursday: Turkiye a terrific golf destination